Experience
About
Our People
Resources
Contact Us
us
canada
uk
Visante
For Hospitals & Health Systems
Hospital Pharmacy Assessment
Ambulatory Pharmacy
Specialty Pharmacy
340B
Employee Pharmacy Benefits
Financial Performance
Sterile Compounding
Pharmacy Automation
Drug Diversion
Antimicrobial Stewardship
Executive Coaching
Population Health Management/Accountable Care
For Pharmaceutical & Healthcare Technology
Strategic Planning
Advisory Boards
Critical Assessments & Mock Committees
Sales & Marketing Support
Implementation Support
Ad Hoc Support
For Government Programs and Managed Care
Medicare
Medicaid
Health Exchanges
Health Plans/Employers
Pharmacy Benefit Management
us
canada
uk
For Hospitals & Health Systems
Hospital Pharmacy Assessment
Ambulatory Pharmacy
Specialty Pharmacy
340B
Employee Pharmacy Benefits
Financial Performance
Sterile Compounding
Pharmacy Automation
Drug Diversion
Antimicrobial Stewardship
Executive Coaching
Population Health Management/Accountable Care
For Pharmaceutical & Healthcare Technology
Strategic Planning
Advisory Boards
Critical Assessments & Mock Committees
Sales & Marketing Support
Implementation Support
Ad Hoc Support
For Government Programs and Managed Care
Medicare
Medicaid
Health Exchanges
Health Plans/Employers
Pharmacy Benefit Management
Experience
About
Our People
Resources
Contact Us
Resources
Visante
/
Visante Insider – October 2019
Publications
Visante Insider – October 2019
Published date: October 17, 2019
In this edition
of the Visante Insider:
USP gives breathing room
Increased scrutiny builds pressure on admin
CMS not giving up on 340B-based payment cuts
Important notice from Genentech re: Emicizumab (HEMLIBRA)
Important notice from DEA
Gene Therapy: Significant Therapeutic Value with Significant Cost
Share this:
Visante
